IP Library Granted Patent US 10,385,476
Granted Patent B2
US 10,385,476 · App. 15/362,692 · Granted Aug 20, 2019

Methods and compositions for the selection and optimization of oligonucleotide tag sequences

Inventors: Norman C. Nelson (San Diego, CA); Jijumon Chelliserry (San Diego, CA)
Assignee: GEN-PROBE INCORPORATED
C40B30/00C07H21/00C12N15/1065C12Q1/6811G16B25/00G16B30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,476
App. No.
15/362,692
Granted
Aug 20, 2019
Kind
B2
Abstract

Methods for selecting tag-oligonucleotide sequences for use in an in vitro nucleic acid assay. The selected tag sequences are useful for nucleic acid assay wherein interference between the nucleic acid sequences is the assay is to be controlled. Selected tag sequences are incorporated into nucleic acid assay to improve the performance of and/or minimize any interference between nucleic acids in the assay compared to untagged assays.

Claims (6)

1. An oligonucleotide comprising a T7 promoter and a tag having the sequence of SEQ ID NO: 113, 107, 117, 118, 119, 122, 123 or 124.

2. The oligonucleotide of claim 1 , wherein the tag has the sequence of SEQ ID NO:117.

3. A method of improving performance of a tag in a transcription mediated amplification assay, comprising

modifying the tag sequence of an oligonucleotide of claim 1 to produce a modified oligonucleotide; and

determining performance of the oligonucleotide in a transcription mediated amplification assay.

4. The method of claim 3 , wherein modifying the tag sequence comprising deleting one or more nucleotides from the sequence.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 041050/0285 Recorded Apr 23, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED
Reel/Frame 075455/0001 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2019
From: HOLOGIC, INC.; CYNOSURE, LLC; CYTYC CORPORATION; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 050719/0701 →
SECURITY INTEREST Recorded Jan 23, 2017
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 041050/0285 →
Continuity (3)
Division 14004107
Provisional Application 61451285 · Mar 10, 2011
Related Publication 20170218435A1 · Aug 3, 2017